Fiche centre
Instituto de Neurologia de Curitiba
Curitiba — Brazil
Essais liés10clinical trials
VilleCuritibalocalisation
PaysBrazillocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04544436
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT05123703 | Operetta 2 — A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04544436 | MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Trontinemab | Alzheimer | Phase 3 | NCT07170150 | TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | RECRUITING |
| Prasinezumab | Parkinson | Phase 3 | NCT07174310 | PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | RECRUITING |
| Telitacicept | Myasthénie | Phase 3 | NCT06456580 | A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | RECRUITING |
| Ocrelizumab Co-formulated With rHuPH20 | SEP | Phase 1 | NCT07667322 | OCARINA 3 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab Test Formulation | SEP | Phase 2 | NCT07074886 | PORTAMENTO — A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 3 | NCT04548999 | GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04586023 | FENhance 2 — Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) | ACTIVE_NOT_RECRUITING |
| Fenebrutinib | SEP | Phase 3 | NCT04544449 | FENtrepid — A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis | ACTIVE_NOT_RECRUITING |